Dexmedetomidine suppressed the rapid increase of cytokine, TNF-α, and IL-6 levels in gastric cancer patients [34] and decreased IL-6 and CRP levels and the inhibition of T-lymphocyte subsets in colon cancer patients undergoing radical surgery [35]. Here, CRP is linked to colonic neoplasm.